Anaphylaxis Induced by Peanut, Tree Nuts Increases on Halloween, Easter
Among Canadian children, the risk for anaphylaxis induced by unknown nuts and peanuts is increased during Halloween and Easter.
Allergies
Dupilumab Gets Breakthrough Therapy Status for Eosinophilic Esophagitis
The designation was based on results from Part A of a double-blind, placebo-controlled, pivotal phase 3 trial.
Benralizumab Looks Promising in Nasal Polyps Trial
The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis.
Plasma Complement C3 Linked to Asthma Exacerbation, Hospitalization Risk
High concentrations of plasma complement C3 may be associated with an increased risk for asthma hospitalizations in the general population and with a high risk for asthma exacerbations in patients with allergic asthma.
Concerns Among Patients Presenting for Drug Allergy Assessment
Patients in the United States who present to their physicians for drug allergy assessments have expressed concerns about their options for medical treatments, experiencing an allergic reaction, and seeking a diagnosis.
Gestational Weight Gain May Be Linked to Childhood Allergic Conditions
Excessive gestational weight gain may be a risk factor for childhood allergic diseases, including asthma and food allergy.
Epitope- and Antigen-Specific IgE Levels May Accurately Predict Peanut Allergy
The use of machine learning algorithms that combine epitope- and antigen-specific IgE levels has been associated with improved accuracy in the prediction of developing peanut allergy.
FDA to Review Omalizumab Prefilled Syringe for Self-Administration
The FDA is expected to make a decision by the first quarter of 2021.
Epinephrine Sublingual Film Receives Fast Track Status for Anaphylaxis
AQST-108 is a sublingual film that delivers systemic epinephrine utilizing the Company’s proprietary technology.
Dupilumab Improves Lung Function in CRSwNP and Comorbid Asthma and COPD Features
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
-
Loading...
-
Loading...
Next post in ATS 2020
